Maria Teresa Mascellino
Stefano Pontone
Alba Edith Vega
Peter Malfertheiner- 1Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy
- 2Department of Surgical Sciences, Sapienza University, Rome, Italy
- 3Faculty of Biochemical Chemistry and Pharmacy, National University of San Luis, San Luis, Argentina
- 4Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-v-Guericke-University, Magdeburg, Germany
Editorial on the Research Topic
Helicobacter pylori infection: pathogenesis, antibiotic resistance, advances and therapy, new treatment strategies
Helicobacter pylori (Hp) is a microorganism discovered only 40 years ago but since then its importance has grown in many pathologies as chronic gastritis, peptic ulcer, gastric carcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma, as well as other endothelial dysfunctions leading to vascular diseases (Ando et al., 2006). Gastric cancer mainly represents the fifth cancer for incidence and the third cause of death in the developed countries (Rawla and Barsouk, 2019). Epidemiology, transmission, and pathogenesis of Hp have been deeply examined as well as the resistance to antibiotics (Eusebi et al., 2014; Kayali et al., 2018; Mascellino et al., 2020). The development of new drugs capable of eradicating this pathogen is highly recommended such as combination therapy or research into other alternatives and new strategies (Makipour and Friedenberg, 2011; Yuan et al., 2021).
The influence of previous therapies in Hp eradication rate is reported in the paper by Choe et al. in which the past use of metronidazole (MZ) is taken into consideration in a group of subjects hospitalized in Korea. It was noted that in patients who underwent the BQT (Bismuth Quadruple Therapy) for 14 days and in those with no MZ previous treatment, the eradication rate was higher than in subjects who underwent the BQT for less than 14 days or in patients with MZ previous use.
The susceptibility of Hp to antibiotics in the different niches of the stomach (antrum and corpus) is another issue based on the microorganism heteroresistance. The authors Goni et al. take into account the severity of atrophic gastritis from the antrum and corpus biopsies, where H. pylori strains were isolated and tested for antibiotics susceptibility. The severity of atrophy seemed to be correlated with the increase in MZ and clarithromycin (CLA) resistance. Thus, the severity of atrophy was a crucial element in order to establish a correct treatment. The high CLA and MZ resistance in atrophic gastritis should be carefully considered.
As far as antibiotic resistance is concerned, interesting is the article by Guo et al. in which the genetic methods (polymerase chain reaction, whole genome sequencing) and the phenotypic method (broth micro-dilution) were compared in H. pylori-infected patients with treatment failure for at least twice in order to assess the efficacy of different antimicrobial resistance–guided quadruple therapies in refractory H. pylori infection. As such, the genotypic resistance determined using gastric biopsy specimens correlated well with the phenotypic resistance both achieving high eradication rates.
The question of whether susceptibility testing is essential in guiding therapeutic strategies has been debated in many studies (Gomollon et al., 2000; Zullo et al., 2003; Graham, 2015).
In this Research Topic, two articles play an important role for this purpose. The first one by Nyssen et al. deals with the comparison of empirical vs. susceptibility-guided Hp treatment. The authors infer that the benefit of susceptibility-guided treatment over empirical therapy could not be demonstrated, even in first-line therapy if the most updated quadruple regimen (BQT) is prescribed.
In the same way in the article by Li P. et al., both susceptibility-guided therapy based on the resistance of CLA or minocycline and empiric quadruple therapy containing furazolidone may achieve the same level of eradication. The empirical quadruple therapy containing furazolidone, bismuth, and esomeprazole might be selected as a correct first-line regimen.
A series of articles in this Research Topic is based on the research for alternative products different from antibiotics and able to treat Hp infection (Ayala et al., 2014; Gopal et al., 2014; Ruggiero, 2014).
For example, Sosa et al. found that new therapies based on plant extracts such as extra virgin olive oil show an effect in vitro on Hp strains and in vivo on the gastric mucosa of mice infected orally with an H. pylori suspension, greatly preventing the formation of the stomach erosions after the treatment.
The same situation is found in the paper of Ibáñez et al. that examines the Hp antimicrobial activity of Asclepias curassavica L. a derivative by a plant from South America and Tropical areas, which was considered a therapeutic adjuvant and a safe nutraceutical product. Asclepain showed an interesting activity towards Hp even against the drug-resistant isolates. The MIC resulted as being 1–2 μg/ml and the MBC between 2 and 4 μg/ml without toxic effects. Its activity was based on the reduction of Hp virulence genes such as ureA, ompA, and flaA.
The following three articles of this Research Topic concern other compounds included in the group of non-antibiotic substances showing an antimicrobial activity. The first study (Jia et al.) takes into consideration the Jinghua Weikang Capsule (JWC) that is the first patent medicine approved in China for the treatment of gastritis and peptic ulcers caused by Hp. Its major component Chenopodium ambrosioides L. inhibits biofilm formation even though the exact mechanism of its efficacy against drug-resistant Hp is still uncertain. It also seems to be able to induce the reversal of MZ resistance.
The second study concerns the use of 1,4-dihydropyridine (DHP)-based antihypertensive drug, which seems to exhibit a strong bactericidal activity against H. pylori. The results presented in this study by González et al. strongly support the use of 1,4-DHP as a tool for novel antimicrobials against H. pylori. The MIC values are reported to be comparable with those achieved by first-line antibiotics.
In the third study, Li R.-J. et al. selected from the natural product forsythia, the Phillygenin, an effective antibacterial component against Hp even if the values of MICs and MBCs are shown to be quite high (16 μg/ml). It was found to be non-toxic to gastric epithelial cells and its mechanism of action was mainly associated with the inhibition of biofilm formation. Phillygenin could also cause ATP leakage in a concentration and time-dependent way. This mechanism seemed to be multiple targets.
In the context of products that can be suitable for helping to combat Hp infection either alone or associated with antibiotics, probiotics play a crucial role. They might interact with the gastric microbiota bringing benefits in the clinical Hp management. These concepts are discussed in the last article by Marinelli et al. who studied Lactococcus rhamnosum (LG) supplementation in combination with BQT (Bismuth Quadruple Therapy) to determine a possible improvement in eradication rate, tolerability, and compliance. The authors found that the influence of LG to BQT in the management of Hp-related infection was very useful in terms of efficacy and tolerability but mainly in the persistence decrease of post-treatment dyspepsia.
In conclusion, Hp antibiotic resistance has been increasing all over the world in recent years, and this phenomenon constitutes an important challenge for the treatment of this fastidious bacterium (Figure 1). This has led to an obstinate search for new solutions such as treatments based on the use of natural resources such as plants, probiotics, nutraceuticals, and bacteriophages. As such, some interesting non-traditional therapies have been indicated in this Research Topic as a mean to target this important gastric pathogen. Notably, it was also shown in this study that successful Hp eradication might be achieved in almost all patients even without susceptibility tests that are expensive and time-consuming.
Figure 1. Overview of different features of Helicobacter pylori management.
Author contributions
MM organized the editorial and wrote the paper. SP revised the manuscript. AV checked the references. PM gave a complete overview of the whole article. All authors contributed to the article and approved the submitted version.
Acknowledgments
I would like to acknowledge Dr. Dania Al Ismail for her support in the preparation of figure and references.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Ando, T., Minami, M., Ishiguro, K., Maeda, O., Watanabe, O., Mizuno, T., et al. (2006). Changes in biochemical parameters related to atherosclerosis after Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 24, 58–64. doi: 10.1111/j.1365-2036.2006.00026.x
Ayala, G., Escobedo-Hinojosa, W. I., de la Cruz-Herrera, C. F., Herrera, C., and Romer, I. (2014). Exploring alternative treatment for Helicobacter pylori infection. World J. Gastroenterol. 20, 1450–1469. doi: 10.3748/wjg.v20.i6.1450
Eusebi, L. H., Zagari, R. M., and Bazzoli, F. (2014). Epidemiology of Helicobacter pylori infection. Helicobacter 19, 1–5. doi: 10.1111/hel.12165
Gomollon, F., Sicilia, B., Ducóns, J. A., Sierra, E., and Revillo, M. J. (2000). Third line treatment for Helicobacter pylori: a prospective, cultured-guided study in peptic ulcer patients. Aliment. Pharmacol. Ther. 14, 1335–1338. doi: 10.1046/j.1365-2036.2000.00833.x
Gopal, R., Jeong, E., Seo, C. H., and Park, Y. (2014). Role of antimicrobical peptides expressed by host cells upon infection by Helicobacter pylori. Protein Pept. Lett. 21, 1057–1064. doi: 10.2174/0929866521666140708092032
Graham, D. Y. (2015). Editorial: avoiding unethical Helicobacter pylori clinical trials: susceptibility-based studies and probiotics as adjuvants. Helicobacter 20, 321–325. doi: 10.1111/hel.12244
Kayali, S., Manfredi, M., Gaiani, F., Bianchi, L., Bizzarri, B., Leandro, G., et al. (2018). Helicobacter pylori, transmission routes and recurrence of infection: state of the art. Acta Biomed. 89, 72–76. doi: 10.23750/abm.v89i8-S.7947
Makipour, K., and Friedenberg, F. K. (2011). The potential role of N-acetylcysteine for the treatment of Helicobacter pylori. J. Clin. Gastroenterol. 45, 841–843. doi: 10.1097/MCG.0b013e31822be4d6
Mascellino, M. T., Oliva, A., Miele, M. C., De Angelis, M., Bruno, G., and Severi, C. (2020). Secondary antibiotic resistance, correlation between genotypic and phenotypic methods and treatment in Helicobacter pylori infected patients: a retrospective study. Antibiotics 9, 549. doi: 10.3390/antibiotics9090549
Rawla, P., and Barsouk, A. (2019). Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz. Gastroenterol. 14, 26–38. doi: 10.5114/pg.2018.80001
Ruggiero, P. (2014). Use of probiotics in the fight against Helicobacter pylori. World J. Gastrointest. Pathophysiol. 5, 384–391. doi: 10.4291/wjgp.v5.i4.384
Yuan, Z., Xiao, S., Li, S., Suo, B., Wang, Y., Meng, L., et al. (2021). The impact OF Helicobacter pylor infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults. Helicobacter 26, e12848. doi: 10.1111/hel.12848
Keywords: Helicobacter pylori infection, molecular diagnostics, antibiotics resistance, non-traditional therapies, updated treatment strategies
Citation: Mascellino MT, Pontone S, Vega AE and Malfertheiner P (2022) Editorial: Helicobacter pylori infection: pathogenesis, antibiotic resistance, advances and therapy, new treatment strategies. Front. Microbiol. 13:1102144. doi: 10.3389/fmicb.2022.1102144
Received: 18 November 2022; Accepted: 21 November 2022;
Published: 08 December 2022.
Edited and reviewed by: Rustam Aminov, University of Aberdeen, United Kingdom
Copyright © 2022 Mascellino, Pontone, Vega and Malfertheiner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maria Teresa Mascellino, bWFyaWF0ZXJlc2EubWFzY2VsbGlubyYjeDAwMDQwO3VuaXJvbWExLml0